These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 1626779

  • 1. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA, Essex-Sorlie D, Vasaune S, Yack R.
    Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of topically administered tissue plasminogen activator for intraocular fibrinolysis in dogs.
    Gerding PA, Hamor RE, Ramsey DT, Vasaune S, Schaeffer DJ.
    Am J Vet Res; 1994 Oct; 55(10):1368-70. PubMed ID: 7998691
    [Abstract] [Full Text] [Related]

  • 3. Effects of intracameral injection of tissue plasminogen activator on corneal endothelium and intraocular pressure in dogs.
    Gerding PA, Essex-Sorlie D, Yack R, Vasaune S.
    Am J Vet Res; 1992 Jun; 53(6):890-3. PubMed ID: 1626778
    [Abstract] [Full Text] [Related]

  • 4. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis.
    Koerner F, Boehnke M.
    Ger J Ophthalmol; 1992 Jun; 1(5):354-60. PubMed ID: 1477641
    [Abstract] [Full Text] [Related]

  • 5. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 6. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P, Morini M, Agnelli G, Ascani A, Nenci GG.
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [Abstract] [Full Text] [Related]

  • 7. Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
    Schmitz K, Greite JH, Bartenschlager EM.
    Ger J Ophthalmol; 1995 Mar; 4(2):75-9. PubMed ID: 7795512
    [Abstract] [Full Text] [Related]

  • 8. Sonothrombolysis for intraocular fibrin formation in an animal model.
    Yamashita T, Ohtsuka H, Arimura N, Sonoda S, Kato C, Ushimaru K, Hara N, Tachibana K, Sakamoto T.
    Ultrasound Med Biol; 2009 Nov; 35(11):1845-53. PubMed ID: 19699025
    [Abstract] [Full Text] [Related]

  • 9. Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery.
    Murray TG, Jaffe GJ, McKay BS, Han DP, Burke JM, Abrams GW.
    Refract Corneal Surg; 1992 Nov; 8(1):44-8; discussion 48-53. PubMed ID: 1554639
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].
    Zhao P, Wang W.
    Zhonghua Yan Ke Za Zhi; 1995 Jul; 31(4):255-8. PubMed ID: 8745515
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
    Xie L, Li S, Dong X, Cao J, Shi W, Guo P.
    Zhonghua Yan Ke Za Zhi; 1998 Jul; 34(4):291-3. PubMed ID: 11877211
    [Abstract] [Full Text] [Related]

  • 12. Effect of immediate postoperative intracameral tissue plasminogen activator (tPA) on anterior chamber fibrin formation in dogs undergoing phacoemulsification.
    Mancuso LA, Nadelstein B, Berdoulay A, Spatola RA.
    Vet Ophthalmol; 2019 Jul; 22(4):477-484. PubMed ID: 30773778
    [Abstract] [Full Text] [Related]

  • 13. [Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery].
    Oficjalska-Młyńczak J, Marek J, Zajac-Pytrus H, Nizankowska MH, Koziorowska M.
    Klin Oczna; 1996 Jul; 98(6):423-5. PubMed ID: 9340414
    [Abstract] [Full Text] [Related]

  • 14. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ, Meijers JC, Levi M, van Gulik TM, Boermeester MA.
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [Abstract] [Full Text] [Related]

  • 15. Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
    Erol N, Ozer A, Topbas S, Yildirim N, Yurdakul S.
    Ophthalmic Surg Lasers Imaging; 2003 May; 34(6):451-6. PubMed ID: 14620747
    [Abstract] [Full Text] [Related]

  • 16. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
    Lam SC, Dieter JP, Strebel LC, Taylor TM, Muscolino G, Feinberg H, Le Breton GC.
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
    [Abstract] [Full Text] [Related]

  • 17. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ, Eisenberg PR, Abendschein DR.
    Blood Coagul Fibrinolysis; 1993 Feb 02; 4(1):7-13. PubMed ID: 8457655
    [Abstract] [Full Text] [Related]

  • 19. [Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations].
    Heiligenhaus A, Schilling H, Schilling M, Mellin KB.
    Ophthalmologe; 1996 Feb 02; 93(1):49-53. PubMed ID: 8867161
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of intraocular penetration of topically administered tissue plasminogen activator in dogs.
    Gerding PA, Eurell TE.
    Am J Vet Res; 1993 Jun 02; 54(6):836-9. PubMed ID: 8323049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.